GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vifor Pharma AG (LTS:0RPD) » Definitions » ROIC %

Vifor Pharma AG (LTS:0RPD) ROIC % : 7.49% (As of Dec. 2021)


View and export this data going back to 2014. Start your Free Trial

What is Vifor Pharma AG ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Vifor Pharma AG's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2021 was 7.49%.

As of today (2024-04-27), Vifor Pharma AG's WACC % is 13.61%. Vifor Pharma AG's ROIC % is 7.38% (calculated using TTM income statement data). Vifor Pharma AG earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Vifor Pharma AG ROIC % Historical Data

The historical data trend for Vifor Pharma AG's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vifor Pharma AG ROIC % Chart

Vifor Pharma AG Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.77 5.63 5.80 6.22 7.44

Vifor Pharma AG Semi-Annual Data
Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.90 4.84 7.35 7.36 7.49

Competitive Comparison of Vifor Pharma AG's ROIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Vifor Pharma AG's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vifor Pharma AG's ROIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vifor Pharma AG's ROIC % distribution charts can be found below:

* The bar in red indicates where Vifor Pharma AG's ROIC % falls into.



Vifor Pharma AG ROIC % Calculation

Vifor Pharma AG's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2021 is calculated as:

ROIC % (A: Dec. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2020 ) + Invested Capital (A: Dec. 2021 ))/ count )
=356.2 * ( 1 - 14.85% )/( (4212.7 + 3939.7)/ 2 )
=303.3043/4076.2
=7.44 %

where

Vifor Pharma AG's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2021 is calculated as:

ROIC % (Q: Dec. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2021 ) + Invested Capital (Q: Dec. 2021 ))/ count )
=357.6 * ( 1 - 16.23% )/( (4058.9 + 3939.7)/ 2 )
=299.56152/3999.3
=7.49 %

where

Note: The Operating Income data used here is two times the semi-annual (Dec. 2021) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vifor Pharma AG  (LTS:0RPD) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Vifor Pharma AG's WACC % is 13.61%. Vifor Pharma AG's ROIC % is 7.38% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Vifor Pharma AG ROIC % Related Terms

Thank you for viewing the detailed overview of Vifor Pharma AG's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vifor Pharma AG (LTS:0RPD) Business Description

Traded in Other Exchanges
N/A
Address
Rechenstrasse 37, Saint Gallen, CHE, 9014
Vifor Pharma AG is a specialty drug manufacturing and licensing company. It researches, develops, and produces its pharmaceutical products and markets and distributes them worldwide. Most of its sales are generated in the USA, with Europe also a strong contributor. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Vifor Pharma AG (LTS:0RPD) Headlines

No Headlines